Ropivacaine
| Evidence Level: L3 | Predicted Indications: 4 |
Table of Contents
Ropivacaine: From Local Anaesthesia to Migraine Disorder
One-Sentence Summary
Ropivacaine is a long-acting amide local anaesthetic, marketed in Canada under six active licences. The TxGNN model predicts it may be effective for migraine disorder, with 2 clinical trials and 3 publications currently supporting this direction. The evidence is small and mostly observational.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the Canadian licence data compiled for this report |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9965 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on general pharmacology, ropivacaine is a long-acting amide local anaesthetic that blocks voltage-gated sodium channels. This is a general characterisation rather than something drawn from the compiled data.
In migraine, local anaesthetics are used as procedural treatments, such as sphenopalatine ganglion blocks, stellate ganglion blocks and trigger point injections. These may interrupt peripheral and parasympathetic pain signalling. They may also reduce trigeminovascular activation and central sensitisation. The mechanism is plausible and clinically actionable as a locally administered therapy.
However, the clinical data are small and varied. Techniques, anatomical targets and patient populations differ across studies, and some studies may not be specific to ropivacaine. The other predictions for this drug are weaker: migraine with brainstem aura, nephrogenic syndrome of inappropriate antidiuresis and dysthymic disorder have no supporting trials or literature.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03666663 | Phase 4 | Completed | 10 | Randomised, double-blind, placebo-controlled trial of sphenopalatine ganglion blocks with nasal anaesthetics for migraine prevention. Very small sample, and may not be ropivacaine-specific. |
| NCT00680823 | Not applicable | Completed | 150 | Paraspinal intramuscular ropivacaine injection for headache in a paediatric emergency department. Indirect evidence: paediatric population and possibly mixed headache types. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35331152 | 2022 | Cohort | BMC Anesthesiology | Observational study of ultrasound-guided stellate ganglion block for relieving migraine pain and improving quality of life |
| 17244105 | 2007 | Cohort | Pain Medicine | Ropivacaine trigger point injections for prophylaxis in severe migraine over 12 weeks |
| 24284858 | 2013 | Cohort | Pain Physician | Revised transnasal topical sphenopalatine ganglion block for headache and facial pain |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02229411 | NAROPIN | Not specified | Not specified |
| 02229418 | NAROPIN | Not specified | Not specified |
| 02229415 | NAROPIN | Not specified | Not specified |
| 02439409 | ROPIVACAINE HYDROCHLORIDE INJECTION, USP | Not specified | Not specified |
| 02439379 | ROPIVACAINE HYDROCHLORIDE INJECTION, USP | Not specified | Not specified |
A sixth licence (DIN 02439387, ROPIVACAINE HYDROCHLORIDE INJECTION, USP) is also valid. All six are single-ingredient products.
Safety Considerations
- Conditions flagged in the knowledge graph (not label text): The knowledge graph links ropivacaine to possible contraindications in several disease groups.
- Respiratory: COPD, respiratory failure, asthma, cor pulmonale
- Cardiovascular: cardiovascular disease, heart disease
- Liver, biliary and renal: liver disease, kidney disease, gallbladder and biliary tract disease, obstructive jaundice
- Neuromuscular: myasthenia gravis, neuromuscular junction disease, butyrylcholinesterase deficiency
- Gastrointestinal and urinary: paralytic ileus, intestinal obstruction, inflammatory bowel disease, benign prostatic hyperplasia, urethral stricture
- Other: substance abuse or dependence, intracranial hypertension These are database associations and should be checked against the official product monograph.
- Drug Interactions: 64 interactions were identified. The sample reviewed included:
- Moderate: obeticholic acid, liposomal morphine, deferasirox, fostamatinib
- Minor: aprepitant, cimetidine, clarithromycin, miconazole, clotrimazole, caffeine, cobicistat, hyaluronidase, ticagrelor
- Unclassified severity: omeprazole, atropine, triamcinolone, simvastatin, epinephrine, iohexol, heparin
Official warnings and contraindications from the Canadian product monograph were not available. Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible and the migraine nerve-block approach has some clinical support. However, the evidence is limited to one very small Phase 4 trial (N=10), one indirect paediatric headache study and three observational studies. There is no completed Phase 2/3 RCT specific to ropivacaine. The decision is therefore to treat this as a research question rather than a development candidate, and the safety review cannot proceed without the official label.
To proceed, the following is needed:
- Canadian product monograph warnings, contraindications and approved indications (currently missing and blocking safety screening)
- Mechanism of action data from DrugBank
- A larger randomised, controlled trial specific to ropivacaine in migraine, with a defined technique, target and population
- Confirmation of route and formulation compatibility, since this use relies on regional nerve block or injection procedures
- Review of the knowledge-graph contraindications and key interactions for the intended patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.